All-In with Chamath, Jason, Sacks & Friedberg

OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze

All-In with Chamath, Jason, Sacks & Friedberg·May 2, 2026

OVERVIEW

This episode covers OpenAI's recent performance struggles and a contrarian view on its product strength, the compute and power constraints facing AI development, and the ongoing legal battle between Elon Musk and OpenAI. It also delves into the massive capital expenditures by tech giants for AI infrastructure and a new class of anti-obesity drugs.

KEY TOPICS

  • OpenAI's missed targets and product performance
  • The "Gay name or Straight name" podcast segment
  • Compute and power constraints in the AI industry
  • Chamath's perspective on market dynamics and supply chain
  • Friedberg's "Rule of 3" for market evolution
  • Pruning techniques in neural networks for efficiency
  • Google's Gemini vs. OpenAI's GPT and market share
  • Cyber security advancements (Mythos, GPT 5.5 Cyber)
  • Musk vs. Altman lawsuit over OpenAI's non-profit status
  • Big Tech's massive CapEx for AI and cloud infrastructure
  • The shift from asset-light to asset-heavy business models
  • Retatrutide and other GLP-1 drugs for weight loss
  • Supreme Court hearing on Monsanto's Roundup case
  • The future of the Supreme Court and political influence

MAIN TAKEAWAYS

  • While OpenAI faced negative press regarding missed revenue and user targets, its latest product, GPT 5.5, is receiving strong developer feedback, suggesting product-level strength.
  • The AI industry is currently bottlenecked by the availability of compute power and energy infrastructure, leading to supply chain delays and potentially impacting growth forecasts for companies like OpenAI and Anthropic.
  • Sam Altman's strategy with OpenAI, despite missing consumer targets, may prove right due to the significant compute commitments that give them an advantage in the booming enterprise and coding markets.
  • Major tech companies are investing unprecedented amounts in CapEx for AI and cloud infrastructure, signaling a significant structural shift from asset-light to asset-heavy business models, which is massively impacting their free cash flow.
  • A new class of triple agonist drugs like Retatrutide shows remarkable results in weight loss, fat reduction, and other health markers, potentially offering life-saving benefits and creating a new high-premium market segment in pharmaceuticals.
  • The Supreme Court case involving Monsanto's Roundup highlights complex legal arguments around federal preemption versus state failure-to-warn laws, with potentially far-reaching implications for regulatory authority and corporate liability.

NOTABLE QUOTES

"Rumination is the path to unhappiness... Go to a beautiful dinner, sit courtside at the Knicks, and do what I've been doing for 30 f***ing years. Recharge maxing."
"What that said to me is that it's not that agents aren't valuable, they are valuable, but they have to be supervised. You know, this idea that you're just going to be able to like automate all the jobs away, it is a massive amount of hand-waving over the real technical problems and issues."
"AI is now synonymous with the growth of the American economy."

Summarized with DriftNote — AI-powered podcast summaries

Try it free